As of 2024-12-14, the EV/EBITDA ratio of Akebia Therapeutics Inc (AKBA) is 9.35. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. AKBA's latest enterprise value is 407.97 mil USD. AKBA's TTM EBITDA according to its financial statements is 43.62 mil USD. Dividing these 2 quantities gives us the above AKBA EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 8.6x - 16.0x | 11.2x |
| Forward P/E multiples | 8.2x - 23.6x | 15.0x |
| Fair Price | 1.63 - 4.69 | 2.60 |
| Upside | -12.0% - 153.5% | 40.8% |
| Date | EV/EBITDA |
| 2024-12-11 | 9.70 |
| 2024-12-10 | 10.00 |
| 2024-12-09 | 10.30 |
| 2024-12-06 | 10.35 |
| 2024-12-05 | 10.20 |
| 2024-12-04 | 10.25 |
| 2024-12-03 | 10.30 |
| 2024-12-02 | 10.75 |
| 2024-11-29 | 10.40 |
| 2024-11-27 | 10.40 |
| 2024-11-26 | 10.35 |
| 2024-11-25 | 9.75 |
| 2024-11-22 | 9.50 |
| 2024-11-21 | 9.20 |
| 2024-11-20 | 9.05 |
| 2024-11-19 | 9.20 |
| 2024-11-18 | 9.10 |
| 2024-11-15 | 9.05 |
| 2024-11-14 | 9.40 |
| 2024-11-13 | 9.70 |
| 2024-11-12 | 9.85 |
| 2024-11-11 | 10.05 |
| 2024-11-08 | 9.80 |
| 2024-11-07 | 9.43 |
| 2024-11-06 | 10.10 |
| 2024-11-05 | 9.40 |
| 2024-11-04 | 9.35 |
| 2024-11-01 | 8.55 |
| 2024-10-31 | 8.40 |
| 2024-10-30 | 8.60 |
| 2024-10-29 | 8.65 |
| 2024-10-28 | 8.25 |
| 2024-10-25 | 8.05 |
| 2024-10-24 | 8.00 |
| 2024-10-23 | 8.05 |
| 2024-10-22 | 8.30 |
| 2024-10-21 | 6.95 |
| 2024-10-18 | 6.80 |
| 2024-10-17 | 6.75 |
| 2024-10-16 | 6.75 |
| 2024-10-15 | 6.65 |
| 2024-10-14 | 6.70 |
| 2024-10-11 | 6.70 |
| 2024-10-10 | 6.50 |
| 2024-10-09 | 6.50 |
| 2024-10-08 | 6.70 |
| 2024-10-07 | 6.70 |
| 2024-10-04 | 6.75 |
| 2024-10-03 | 6.70 |
| 2024-10-02 | 6.80 |